ArticleMolecular psychiatry2012
Targeting the BH3-interacting domain death agonist to develop mechanistically unique antidepressants.
O Malkesman et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
13 papers cite it
this papercites it